functional medicine and nutritional genomics - American Association ...

AAPI’S NUTRITION GUIDE TO OPTIMAL HEALTH: USING PRINCIPLES OF FUNCTIONAL MEDICINE AND NUTRITIONAL GENOMICS
xxii
Morgentaler, A. (2009). Testosterone and Prostate
Safety. Front Horm Res, 197-203.
xxiii Lee JR. (2003). Hormone Balance for Men.
xxiv
Stein, D. (2008). Does progesterone have
neuroprotective properties? Ann Emerg Med,
164-172.
Additional resources:
Campagnoli, C. (2005). Pregnancy, preogesterone and
progestins in relation to breast cancer risk. J.
Steroid Biochem Mol Biol, 441-450.
Cheng, W. (1999). Two antiarherogenic effects of
progesterone on human macrophages; Inhibition
of cholesteryl ester synthesis and block of its
enhancement by glucocorticoids. J Clin
Endocrinol Metab, 265-71.
Cook, D. (1999). Route of estrogen administration
helps determine growth hormone (GH)
replacement dose in GH-deficient adults. J Clin
Endocrinol Metab, 3956-3960.
CT, M. (2000). The perils of portliness: causes and
consequences of visceral adiposity. Diabetes,
883-888.
Gozansky, W. (2005). Salivary cortisol determined by
enzyme immunoassay is preferable to serum
total cortisol for assessment of dynamic
hypothalamic-pituitary-adrenal axis activity. Clin
Endocrin, 336-341.
Holtorf, K. (2009). The bioidentical hormone debate:
Are bioidentical hormones (estradiol, estriol and
progesterone) safe or more efficacious than
commonly used synthetic versions in hormone
replacement therapy? Postgrad Med, 73-85.
Khan-Dawood, F. (1984). Salivary and plasma bound
and "free" testosterone in men and women. Am
J Obst and Gyn, 441-449.
Laidlaw, I. (1995). The proliferation of normal breast
tissue implanted into athymic nude mice is
stimulated by estrogen, but not by progesterone.
Endocrinology, 164-171.
Lee, J. (1990). Osteoporosis Reversal: The Role of
Progesterone. International Clinical Nutrition
Review.
Lemon, H. (1975). Estriol prevention of mammary
carcinoma induced by 7,12dimethylbenzanthracene
and procarbazine. Cancer
Res, 1341-1353.
168
Lemon, H. (1989). Inhibition of radiogenic mammary
carcinoma in rats by estriol or tomoxifen.
Cancer, 1685-1692.
Morgentaler, A. (2003). Testosterone replacement
therapy in hypogonadal men at high risk for
prostate cancer: results of 1 year of treatment
in men with prostatic intraepithelial neoplasia.
Journal of Urology, 2348-2351.
Morgentaler, A. (2008). Does testosterone therapy
increase the risk of prostate cancer? Endocrin
Pract, 904-911.
Otsuki, M. (2001). Progesterone but not
medroxyprogesterone, inhibits vascular cell
adhesion molecule-1 expression in human
vascular endothelial cells. Arterioscler Thromb
Vasc Biol., 243-2.
Pasqualini, J. (1998). Progestins and breast cancer.
Steroid Biochem Mol Biol, 225-235.
Plu-Bureau, G. (1999). Percutaneous progesterone use
and risk of breast cancer: Results from a french
cohort study of permenopausal women with
benign breast disease. Cancer Detect Prev,
290-296.
Sannikka, E. (1983). Testosterone concentrations in
human seminal plasma and saliva and its
correlation with non-protein-bound and total
testosterone levels in serum. Int J Androl, 319-
30.
Schultheiss, S. (2004). Testosterone therapy in the
aging male: What about the prostate?
Androlagia, 355-365.
Sitruk-Ware. (1980). Treatment of benign breast
disease by progesterone applied topically.
International Symposium on Percutaneous
Absorption of Steroids, (pp. 219-229).
Stanczyk, F. (2005). Percutaneous Administration of
Progesterone: Blood levels and endometrial
protection. Menopause, 232-237.
Tokai, J. (2009). Beneficial aspect of oral estriol as
hormone replacement therapy: Considerations on
bone and lipid metabolism. J Exp Clin Med,
91-98.
Vining, R. (1986). Hormones in Saliva. Critical Reviews
in Clinical Laboratory Sciences, 95-146.
Wang, C. (1981). Salivary testosterone in men: Further
evidence ofa direct correlation with free serum
testosterone. J Clin Endocrin Metab, 1021-4.
Wen-Sen, L. (1997). Progesterone inhibits arterial
smooth muscle cell proliferation. Natural
Medicine, 1005-1008.
2012